A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma

Trial Profile

A Randomized, Double-blind, Repeat Dose Cross-over Study to Assess the Bronchodilator Effects of Once Daily QVM149 Following Morning or Evening Dosing for 14 Days Compared to Placebo in Patients With Asthma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Glycopyrrolate/indacaterol/mometasone (Primary)
  • Indications Asthma
  • Focus Therapeutic Use
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 16 Apr 2018 This trial has been completed in Germany, according to European Clinical Trials Database
    • 11 Jan 2018 Planned end date changed from 19 Apr 2018 to 26 Apr 2018.
    • 11 Jan 2018 Planned primary completion date changed from 19 Apr 2018 to 26 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top